Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2011

EC Sanction of DuoCort’s Plenadren Triggers ViroPharma’s $33M Acquisition of Swedish Firm

  • EC approval of DuoCort’s Plenadren® (hydrocortisone modified release tablet) therapy for adrenal insufficiency in adults marks the go-ahead for ViroPharma to acquire the Swedish specialty pharma firm. The definitive agreement for ViroPharma to acquire DuoCort, announced in October, was dependent on EC approval of Plenadren, and the drug’s clearance by the regulator means the firms now expect to complete the acquisition in November. On closing, ViroPharma will pay $33 million up front, and could in addition pay another $130 million, associated with manufacturing, sales thresholds, and territory expansion.

    The EC’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on Plenadren in July. Final approval means the drug is now cleared for marketing in all countries of the EU, plus Iceland, Norway, and Lichtenstein.

    Plenadren is a once-daily, dual-release oral glucocorticoid therapy that combines both rapid release and extended release characteristics in a single tablet.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »